Home › Triple-Negative Breast Cancer › Maine
Triple-Negative Breast Cancer clinical trials in Maine
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in Maine.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- New England Cancer Specialists ( Site 0051), Westbrook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- New England Cancer Specialists, Scarborough
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Eastern Maine Medical Center, Brewer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT04468061From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.